Transgene to present data on its two therapeutic cancer vaccines at the 2023 ASCO annual meeting
Category: Press release
Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors
Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001
Transgene provides business update and Q1 2023 financial position
business update and Q1 2023 financial position 15
Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer
First patient dosed in Phase I trial evaluating TG6050 15
Transgene’s Combined General Meeting of May 5, 2023
Transgene’s combined general meeting 15
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio 15
New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
New Data Showing that Transgene and NEC’s TG4050 induces strong and specific immune responses against tumors presented at AACR 15
Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
Preclinical results showing TG6050 induces tumor regression by activating innate and adaptive immune responses 15
Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
Appointment of Carol Stuckley as New Independent Director 15
Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023
Availability of Preparatory documents for the combined general meeting of May 5, 2023 15
